U.S. Patent and Trademark Office, U.S. DEPAR Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10573134	
Filing Date		2006-03-23	
First Named Inventor Pable		Steinberg	
Art Unit			_
Examiner Name			_
Attorney Docket Numb	or	101215,219	_

					U.S.I	PATENTS			Remove	
Examiner Cite Initial* No Patent Number Kind Code1 Iss		Issue E	Date	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	6586177	B1	2003-0	7-01	Shuber		Entire o	document	
If you wis	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee of Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20020086386	A1	2002-0	7-04	Kamb et al.		Entire o	document	
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or v	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	+-
	1	01/18252	wo		A2	2001-03-15	Exact Laboratories	inc.	Entire document	_
	2	99/04037	wo			1999-01-28	Zeneca Limited		Entire document	Г
	3	698 14 622	DE		T2	2004-02-26	Univ Johns Hopkin	s I	Entire document	-

	4	197 36 691	DE	A1	1999-02-25	Michael Glesing	Entire document				
If you wis	h to a	dd additional Foreign P	tent Document	citation	information pl	lease click the Add butto	Add	\neg			
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city andictor country where published.										
	1	Salahshor Sima et al. "Colorectal Cancer With and Without Microsatellite Instability Involved Different Genes"; Genes Chromosomes and Cancer, Volume 26, Number 3, November 1999, pages 247-252.									
	2	Rajapopelan H et al.: "RAF/RAS Oncogenes and Mismatch-Repair Status", Nature, MacMillan Journals Ltd.; London; Uourne 418, Number 20, August 2002; page 934.									
	3	Davies H et al.; "Mutations of the BRAF Gene in Human Canoer"; Nature, MacMillan Journals Ltd., London; Volume 417, number 6892, June 27, 2002, pages 949-954.									
	4	Yuen S T et al. "Similarity of the Phenotypic Patients Associated with BRAF and KRAS Mutations in Colorectal Neoplass": Cancer Research, American Association for Cancer Research, Baltimore, MD, Volume 62, Number 22, (November 15, 2002, pages 4641-446).									
	5	Prix Lothar et al: "Diagnostic Blochip Array for First and Sensitive Detection of K-ras Mutations in Stool", Clinical Chemistry, Volume 48, Number 3, March 2002, pages 428-435.									
	6	Dong Seung Myung et al.; 'Detecting Colorectal Cancer in Stool With the Use of Multiple Genetic Targets', Journal of the National Cancer Institute; Volume 93, Namber 11, June 6, 2001, pages 858-865.									
	7	CA abstract AN 138.335	441.								

If you wish to add additional non-patent literature document citation information please click the Add button Add

	Application Number		10573134
INFORMATION DIGGS COURT	Filing Date		2006-03-23
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Pable		Steinberg
(Not for submission under 37 CFR 1.99)	Art Unit		
(NOTION SAUSINGSSON GROCE OF OTHER 1884)	Examiner Name		
	Attorney Docket Numb	er	101215-219

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
SEVAMINED: Initial if	Denvi line through a					

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Knd Codes of USPTO Patent Documents at your USPTO GDV or MREP 901 06. * Enter office that issued the document, by the howleter code (NIPO Standard ST.S.). For Jupanese patent documents, he accusion of the year of the right of the Emperor must precise the sent contract of the patent document. **
**Hord of document by the appropriate shronly an exclusion of the contract short Wileo Standard ST.S.E. Standard S

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10573134				
Filing Date		2006-03-23				
First Named Inventor Pable		Steinberg				
Art Unit						
Examiner Name						
Attorney Docket Number		101215-219				

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/bruce s londa/	Date (YYYY-MM-DD)	2006-06-15
Name/Print	Bruce S. Londa	Registration Number	33531

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.